Clinical Trial Update: Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bone mineral density changes and safety of rhBMP-2/CPM in subjects with decreased bone mineral density (osteoporosis).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• rhBMP-2/CPM (recombinant human bone morphogenetic protein-2 with calcium phosphate matrix)

Snippet

Sponsor: Pfizer | Conditions: Osteoporosis | Phase 2 | Status: COMPLETED | Results posted: 2020-03-20